Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Acquisition and loss rates and estimates of duration of oral and vaginal Candida species colonization and candidiasis were examined among 868 human immunodeficiency virus (HIV)-seropositive and 437 at-risk HIV-seronegative women monitored prospectively during 1993-1999. Colonization and candidiasis acquisition rates, both oral and vaginal, were significantly higher among HIV-seropositive women; the magnitude of increase in candidiasis outcomes for HIV-seropositive women was greater for oral candidiasis than for vaginal candidiasis. Loss rates and estimates of duration of incident outcomes indicated that persistent mucosal colonization was more likely among HIV-seropositive women. However, results did not suggest persistent mucosal candidiasis. Higher HIV loads were significantly associated with increased odds of incident or persistent oral and vaginal colonization and candidiasis, an effect significantly reduced by highly active antiretroviral therapy for the incident outcomes of oral candidiasis and vaginal colonization. Cell-mediated immunodeficiency (CD4(+) lymphocyte count <500 cells/mm(3)) was significantly associated with increased odds of oral colonization or candidiasis, but not with vaginal colonization or candidiasis. In HIV-seropositive women, mucosal candidiasis is the consequence of multiple interacting factors.
Ohmit
Suzanne E
SE
Wayne State University School of Medicine, Detroit, Michigan, USA. sohmit@umich.edu
Sobel
Jack D
JD
Schuman
Paula
P
Duerr
Ann
A
Mayer
Kenneth
K
Rompalo
Anne
A
Klein
Robert S
RS
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology* / Q000382:microbiology; D000328:Adult; D019380:Anti-HIV Agents; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002175:Candida / Q000302:isolation & purification*; D002180:Candidiasis, Oral / Q000150:complications* / Q000453:epidemiology*; D002181:Candidiasis, Vulvovaginal / Q000150:complications* / Q000453:epidemiology*; D002353:Carrier State / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000382:microbiology / Q000821:virology; D006801:Humans; D016015:Logistic Models; D008137:Longitudinal Studies; D009960:Oropharynx / Q000382:microbiology; D012307:Risk Factors; D014621:Vagina / Q000382:microbiology; D019562:Viral Load
D019380:Anti-HIV Agents